Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03463460 · ClinicalTrials.gov registry record · Phase 2

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

A Phase 2 study of Thymic Carcinoma, sponsored by Dwight Owen.

Active
Registry status
Phase 2
Development phase
9
Enrollment target
3
Study locations

NCT03463460 is a Phase 2 study of Thymic Carcinoma that is active but no longer recruiting, run by Dwight Owen. The registered enrollment target is 9 participants, below the 46-participant average among 4 other Thymic Carcinoma trials with a reported enrollment target (80% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03463460, a Phase 2 study of Thymic Carcinoma, is active but no longer recruiting, sponsored by Dwight Owen.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
9 participants
Enrollment target
3
Study locations

Study Summary

This phase II trial studies how well pembrolizumab and sunitinib malate work in treating participants with thymic cancer that has spread to other places in the body or cannot be removed by surgery and does not respond to treatment. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and sunitinib malate may work better in treating thymic cancer.

Conditions Studied

Thymic Carcinoma

Interventions

  • BIOLOGICAL Pembrolizumab
  • OTHER Laboratory Biomarker Analysis
  • DRUG Sunitinib Malate

Study Locations (3)

Florida

  • Moffitt Cancer Center - Tampa

Indiana

  • Indiana University - Indianapolis

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2018-06-19
Est. Completion 2027-04-30
Phase Phase 2

Sponsor

Dwight Owen

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03463460

The ClinicalTrials.gov registry entry for NCT03463460 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 46-participant average among 4 other Thymic Carcinoma trials with a reported enrollment target (80% lower). The listed sponsor is Dwight Owen, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Thymic Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.

NCT03463460 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Indiana, Ohio.

Frequently Asked Questions

What is clinical trial NCT03463460 about?

NCT03463460 is a clinical study titled "Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer". This phase II trial studies how well pembrolizumab and sunitinib malate work in treating participants with thymic cancer that has spread to other places in the body or cannot be removed by surgery and does not respond to treatment. Monoclonal antibodies, such as pembrolizumab, may interfere with the...

What is the current status of trial NCT03463460?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2018-06-19. Estimated completion is 2027-04-30.

What conditions does trial NCT03463460 study?

This clinical trial studies the following conditions: Thymic Carcinoma.

What interventions are being tested in trial NCT03463460?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Sunitinib Malate (DRUG).

Who is sponsoring clinical trial NCT03463460?

This trial is sponsored by Dwight Owen, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03463460 being conducted?

This trial has 3 study locations across Florida, Indiana, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Thymic Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Thymic Carcinoma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.